ArticleTherapeutic advances in medical oncology2024

A prospective phase II single-arm study and predictive factor analysis of irinotecan as third-line treatment in patients with metastatic gastric cancer.

Nuoya Yu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.